Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
A clinical syndrome characterized by palpitation, SHORTNESS OF BREATH, labored breathing, subjective complaints of effort and discomfort, all following slight PHYSICAL EXERTION. Other symptoms may be DIZZINESS, tremulousness, SWEATING, and INSOMNIA. Neurocirculatory asthenia is most typically seen as a form of anxiety disorder.
Eponyms in medicine are terms that are named after a person, typically the physician or scientist who first described the disease, condition, or procedure, such as Alzheimer's disease or Parkinson's disease.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Deoxycytidine is a nucleoside consisting of the pentose sugar deoxyribose linked to the nitrogenous base cytosine, which plays a crucial role in DNA replication and repair processes within cells.
The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
A decrease in the number of NEUTROPHILS found in the blood.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Thiophenes are aromatic heterocyclic organic compounds containing a five-membered ring with four carbon atoms and one sulfur atom, which are found in various natural substances and synthesized for use in pharmaceuticals and agrochemicals.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The forcible expulsion of the contents of the STOMACH through the MOUTH.
Organic compounds which contain platinum as an integral part of the molecule.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer of the LUNG.
The giving of drugs, chemicals, or other substances by mouth.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Quinazolines are heterocyclic aromatic organic compounds consisting of a benzene ring fused to a pyrazine ring, which are synthesized and used as intermediates in pharmaceuticals, particularly in the production of various drugs such as antimalarials, antihypertensives, and antitumor agents.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Tumors or cancers of the KIDNEY.
Antimetabolites that are useful in cancer chemotherapy.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
Tumors or cancer of the human BREAST.
The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
Compounds that specifically inhibit the reuptake of serotonin in the brain.
A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.

Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. (1/55)

Docetaxel has shown remarkable radiosensitizing in vitro properties. In a previous phase I/II dose escalation study in non-small-cell lung cancer (NSCLC) we observed a high response rate after concomitant boost radiotherapy and weekly docetaxel. The maximum tolerated dose was 30 mg m(-2) week(-1). In the present phase II study we evaluated whether weekly docetaxel and conventionally fractionated radiotherapy could be better tolerated and equally effective in the treatment of locally advanced NSCLC. Thirty-five patients with T3, T4/N2, T3/M0-staged disease were recruited. Docetaxel (30 mg m(-2)) was given as a 30 min infusion once a week. Asthenia and radiation-induced oesophagitis were the main side-effects of the regimen enforcing 2-week treatment delay in 6/35 (17%) patients and minor delay (3-7 days) in another 11/35 (31%) patients. Neutrophil, platelet and haemoglobin toxicity was minimal, but pronounced lymphocytopenia was observed. Complete response (CR) of the chest disease was observed in 12/35 (34%) patients and partial response in 16/35 (46%). Although not statistically significant (P=0.19), a higher CR rate (8/18; 44%) was observed in patients who accomplished their therapy within the scheduled treatment time (44-47 days) as compared to patients that interrupted their treatment for several days due to treatment-related toxicity (CR 4/17; 23%). The overall survival and the local progression-free survival at 1 year was 48% and 60% respectively. We conclude that docetaxel combination with radiotherapy is a promising approach for the management of locally advanced NSCLC that results in high CR rate. Further trials with docetaxel-based radiochemotherapy should integrate accelerated radiotherapy together with cytoprotection.  (+info)

Collagen dysplasia (cutaneous asthenia) in a cat. (2/55)

Hereditary collagen dysplasias comprise a complex group of connective-tissue disorders that result in the reduced tensile strength of affected tissues. These processes are called cutaneous asthenia in the skin of dogs and cats. We report here the case of a crossbred male cat, aged 6 months, that presented with two skin wounds in the region of the right thorax and right iliac tuberosity. The skin of these regions and of the animal's dorsum was hyperextensible, smooth to the touch, and easily torn with minor trauma. Microscopic examination of skin samples revealed reduced dermal connective tissue consisting of shortened and fragmented collagen fibers. Normal fibers were intermingled with altered fibers. Ultrastructural changes in collagen fibers included disorientation of fibrils within the same bundle, marked spacing differences, and variation in the diameter of transverse sections. The fibrils maintained the transverse striations characteristic of normal collagen.  (+info)

Sequelae of sarin toxicity at one and three years after exposure in Matsumoto, Japan. (3/55)

In order to clarify the later sequelae of sarin poisoning that occurred in Matsumoto City, Japan, on June 27, 1994, a cohort study was conducted on all persons (2052 Japanese people) inhabiting an area 1050 meters from north to south and 850 meters from east to west with the sarin release site in the center. Respondents numbered 1237 and 836 people when surveys were conducted at one and three years after the sarin incident, respectively. Numbers of persons with symptoms of sarin toxicity were compared between sarin victims and non-victims. Of the respondents, 58 and 46 people had symptoms associated with sarin such as fatigue, asthenia, shoulder stiffness, asthenopia and blurred vision at both points of the survey, respectively. The prevalences were low; some complained of insomnia, had bad dreams, difficulty in smoking, husky voice, slight fever and palpitation. The victims who had symptoms one year after the incident had a lower erythrocyte cholinesterase activity than did those who did not have symptoms at the early stage; such persons lived in an area with a 500 meter long axis north east from the sarin release site. The three-year cohort study clearly showed that the odds ratios of almost all of the symptoms were high in the sarin-exposed group, suggesting a positive relationship between symptoms and grades of exposure to sarin. These results suggest that symptoms reported by many victims of the sarin incident are thought to be sequelae related to sarin exposure.  (+info)

Interferon treatment of chronic hepatitis C in patients cured of pediatric malignancies. (4/55)

BACKGROUND AND OBJECTIVE: Chronic hepatitis C was a frequent complication in patients treated for malignancy until the introduction of anti-HCV screening tests for blood donors. The association between chronic hepatitis C and progression to cirrhosis and hepatocellular carcinoma has been reported in about 20% and 5% of patients, respectively, within 20-30 years of infection. In adult patients, interferon has proved to be effective in decreasing the abnormal values of transaminases and the level of HCV viremia. Our purpose was to assess efficacy of and tolerance to interferon in a group of young patients who had acquired HCV infection during a period of chemotherapy. DESIGN AND METHODS: Interferon-a (IFN) was administered to 26 adolescents and young adults (13 males, age range 17-36 years; median age 24) with chronic hepatitis C, including 4 with hepatitis B virus co-infection, who had been treated for leukemia or solid tumor 5 to 19 years before joining this trial. Patients were treated with natural IFN alpha at a dose of 4 MU/m(2) thrice weekly for 12 months and followed up for another 6 months thereafter. RESULTS: Nine patients stopped treatment during the first 6 months because of side effects (2 cases) or lack of response. At the end of the trial, 8 (31%) cases had responded, with alanine amino-transferase normalization and clearance of hepatitis C virus (HCV) RNA. A sustained response was only documented in 15% of cases, however, irrespective of any hepatitis B virus co-infection. The 2 patients with HCV genotype 2 were both responders, whereas only 8% of those with genotype 1 responded. INTERPRETATION AND CONCLUSIONS: These data show that the efficacy of IFN in this series of young patients is similar to that reported for otherwise healthy adults with hepatitis C. Patients with genotype 2 are strong candidates for IFN treatment while other therapeutic strategies should be designed for patients with HCV genotype 1.  (+info)

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. (5/55)

PURPOSE: Flavopiridol is the first cyclin-dependent kinase (cdk) inhibitor to enter clinical trials. Serum levels of flavopiridol obtained during phase I studies were sufficient to inhibit in vitro cancer cell growth. Because responses were observed in kidney cancer patients in the phase I trials, we performed a phase II trial of flavopiridol in this patient population. PATIENTS AND METHODS: Thirty-five minimally pretreated patients were accrued using a standard two-step mechanism. Flavopiridol (50 mg/m(2)/d) was administered by continuous infusion for 72 hours every 2 weeks, and response was evaluated every 8 weeks. Peripheral blood mononuclear cells (PBMCs) were collected at baseline, at completion of drug infusion, and on day 7 of the first therapy cycle, and cell cycle parameters after phytohemagglutinin and interleukin-2 stimulation were assessed. RESULTS: There were two objective responses (response rate = 6%, 95% confidence interval, 1% to 20%). The most common toxicities were asthenia, occurring in 83% of patients (grade 3 or 4 in 9%), and diarrhea, occurring in 77% of patients (grade 3 or 4 in 20%). Also, nine patients (26%) experienced grade 3 or 4 vascular thrombotic events, including one myocardial infarction, two transient neurologic ischemic attacks, four deep venous thrombosis, and two pulmonary emboli. Cell cycle studies did not reveal any effect of flavopiridol on stimulated PBMCs. CONCLUSION: Flavopiridol, at the dose and schedule administered in this trial, is ineffective in metastatic renal cancer. In addition to the diarrhea observed in phase I studies, we also observed a higher incidence of asthenia and serious vascular thrombotic events than expected.  (+info)

Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. (6/55)

AIMS: To investigate the effects of sibutramine in combination with alcohol in a double-blind, randomised, placebo-controlled, four-way crossover study in 20 healthy volunteers. METHODS: On each study day each volunteer received either: sibutramine 20 mg+0.5 g kg-1 alcohol; sibutramine 20 mg+placebo alcohol; placebo capsules+0.5 g kg-1 alcohol; or placebo capsules+placebo alcohol. Alcohol was administered 2 h following ingestion of the study capsules. During each study day, assessments of cognitive performance were made prior to dosing, and at 3, 4.5, 6 and 10 h post dosing. Blood alcohol concentration was estimated using a breath alcometer immediately prior to each cognitive performance test session. Each study day was followed by a minimum 7 day washout period. RESULTS: Alcohol was found to produce statistically significant impairments in tests of attention (maximum impairment to speed of digit vigilance=49 ms) and episodic memory (maximum impairment to speed of word recognition=74 ms). Alcohol also increased body sway (maximum increase 17.4 units) and lowered self rated alertness (maximum decrease 13.6 mm). These effects were produced by an inferred blood alcohol level of 53.2 mg dl-1. Sibutramine was not found to potentiate any of the effects of alcohol. There was a small, yet statistically significant, interaction effect observed on the sensitivity index of the picture recognition task. In this test, the combined effects of sibutramine and alcohol were smaller than the impairments produced by alcohol alone. Sibutramine, when dosed alone, was associated with improved performance on several tasks. Sibutramine improved attention (mean speed of digit vigilance improved by 21 ms), picture recognition speed (improvement at 3=81) and motor control (tracking error at 3 h reduced by 1.58 mm). Also sibutramine improved postural stability (reducing body sway at 3 h by 14.2 units). Adverse events reported were unremarkable and consistent with the known pharmacology of sibutramine and alcohol. CONCLUSIONS: There was little evidence of a clinically relevant interaction of sibutramine with the impairment of cognitive function produced by alcohol in healthy volunteers. The single statistically significant interaction indicated a reduction, rather than a worsening, of alcohol-induced impairment when sibutramine is taken concomitantly. Sibutramine when administered alone is associated with improved performance on several tasks.  (+info)

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. (7/55)

Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds. Thirty-three patients were treated with capecitabine administered orally twice daily on days 1-14, and docetaxel given as a 1 h intravenous infusion on day 1. Treatment was repeated every 3 weeks. The dose of capecitabine ranged from 825 to 1250 mg m(-2) twice a day and of docetaxel from 75 to 100 mg m(-2). The dose-limiting toxicity (DLT) was asthenia grade 2-3 at a dose of 1000 mg m(-2) bid of capecitabine combined with docetaxel 100 mg m(-2). Neutropenia grade 3-4 was common (68% of courses), but complicated by fever in only 2.4% of courses. Other non-haematological toxicities were mild to moderate. There was no pharmacokinetic interaction between the two drugs. Tumour responses included two complete responses and three partial responses. Capecitabine 825 mg m(-2) twice a day plus docetaxel 100 mg m(-2) was tolerable, as was capecitabine 1250 mg m(-2) twice a day plus docetaxel 75 mg m(-2).  (+info)

Efficacy and safety of haemodialysis treatment with the Hemocontrol biofeedback system: a prospective medium-term study. (8/55)

BACKGROUND: Hypovolaemia has been implicated as a major causal factor of morbidity during haemodialysis (HD). A model biofeedback control system for intra-HD blood volume (BV) changes modelling has been developed (Hemocontrol), Hospal Italy) to prevent destabilizing hypovolaemia. It is based on an adaptive controller incorporated in a HD machine (Integra), Hospal Italy). The Hemocontrol biofeedback system (HBS) monitors BV contraction during HD with an optical device. HBS modulates BV contraction rates by adjusting the ultrafiltration rate (UFR) and the refilling rate by adjusting dialysate conductivity (DC) in order to obtain the desired pre-determined BV trajectories. METHODS: Nineteen hypotension-prone uraemic patients (seven males, 12 females; mean age 64.5+/-3.0 SEM years; on maintenance HD for 80.5+/-13.2 months) volunteered for the present prospective study that compared the efficacy and safety of bicarbonate HD treatment equipped with HBS, as a whole, with the gold-standard bicarbonate treatment equipped with a constant UFR and DC (BD). The study included three phases: Medium-term studies started with one period of 6 months of BD and always had a follow-up period of HBS treatment ranging from 14 to 30 months (mean 24.0+/-1.6); short-term studies started in September 1999, when all patients went back to BD treatment for a wash-out period of 4 weeks and a short-term study period of a further 3 weeks (phase A). Afterwards, they once again started HBS treatment for a wash-out period of 4 weeks and a short-term study period of a further 3 weeks (phase B). Every patient underwent acute studies during a single HD run, once during phase A and once in phase B. Resistance (R) and reactance (Xc) measurements were obtained utilizing a single-frequency (50 kHz) tetrapolar bioimpedance analysis (BIA). Extracellular fluid volume (ECV) was calculated from R, Xc, and height and body weight measurements using the conventional BIA regression equations. RESULTS: The overall occurrence of symptomatic hypotension and muscle cramps was significantly less in HBS treatment in both medium- and short-term studies. Self-evaluation of intra- and inter-HD symptoms (worst score=0, best score=10) revealed a statistically significant difference, as far as post-HD asthenia was concerned (6.2+/-0.2 in HBS treatment vs 4.3+/-0.1 in BD treatment, P<0.0001). No difference was observed between the two treatments when comparing pre- and post-HD lying blood pressure, heart rate, body weights and body weight changes in medium- and short-term studies. The residual BV%/ Delta ECV% ratio, expression of the vascular refilling, was significantly higher during HBS treatment in acute studies. CONCLUSIONS: HBS treatment is effective in lowering hypovolaemia-associated morbidity compared with BD treatment; this could be related to a greater ECV stability. Furthermore, HBS is a safe treatment in the medium-term because these results are not achieved through potentially harmful changes in blood pressure, body weight, and serum sodium concentration.  (+info)

Asthenia is a medical term that refers to a condition of unusual physical weakness or exhaustion that is not relieved by rest. It can be a symptom of various underlying health issues, such as infections, neurological disorders, endocrine diseases, and mental health conditions. Asthenia should not be confused with general fatigue or tiredness, as it is more severe, persistent, and debilitating.

The term "asthenia" comes from the Greek words "a" (without) and "sthenos" (strength), which together mean "without strength." In medical contexts, asthenia is often used to describe a significant decrease in muscle strength or energy levels that interferes with daily activities and reduces the overall quality of life.

Asthenia can manifest as a general feeling of weakness, fatigue, lethargy, or lack of stamina. In some cases, it may be accompanied by other symptoms such as dizziness, lightheadedness, headaches, irritability, and depression. Depending on the underlying cause, asthenia may be treated with various interventions, including medication, lifestyle changes, physical therapy, or counseling.

Neurocirculatory asthenia is not a term that is widely used in modern medicine. However, historically, it has been used as a descriptive diagnosis for a group of symptoms characterized by fatigue, weakness, dizziness, and disturbances of heart rate and blood pressure, often in response to emotional stress or physical exertion.

The term "neurocirculatory" refers to the interaction between the nervous system and the cardiovascular system, while "asthenia" is a general term used to describe a lack of energy or weakness.

In modern medicine, this condition may be diagnosed as a form of functional disorder, neurasthenia, or somatic symptom disorder, depending on the specific symptoms and underlying causes. It's important to note that while these symptoms can be real and debilitating, they do not have a clear organic cause, and treatment typically focuses on managing symptoms and addressing any underlying psychological or emotional factors.

An eponym is a name derived from a person, usually the person who first described a medical condition or invention. In medicine, eponyms are often used to describe specific signs, symptoms, conditions, or diagnostic tests. For example, Alzheimer's disease is named after Alois Alzheimer, who first described the condition in 1906. Similarly, Parkinson's disease is named after James Parkinson, who first described it in 1817.

Eponyms can be helpful in medical communication because they provide a quick and easy way to refer to specific medical concepts. However, they can also be confusing or misleading, especially when the eponym's origin is not well-known or when different eponyms are used for the same concept. Therefore, it is essential to use eponyms appropriately and understand their underlying medical concepts.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Taxoids are a class of naturally occurring compounds that are derived from the bark of the Pacific yew tree (Taxus brevifolia) and other species of the genus Taxus. They are known for their antineoplastic (cancer-fighting) properties and have been used in chemotherapy to treat various types of cancer, including ovarian, breast, and lung cancer.

The most well-known taxoid is paclitaxel (also known by the brand name Taxol), which was first discovered in the 1960s and has since become a widely used cancer drug. Paclitaxel works by stabilizing microtubules, which are important components of the cell's skeleton, and preventing them from disassembling. This disrupts the normal function of the cell's mitotic spindle, leading to cell cycle arrest and ultimately apoptosis (programmed cell death).

Other taxoids that have been developed for clinical use include docetaxel (Taxotere), which is a semi-synthetic analogue of paclitaxel, and cabazitaxel (Jevtana), which is a second-generation taxoid. These drugs have similar mechanisms of action to paclitaxel but may have different pharmacokinetic properties or be effective against cancer cells that have developed resistance to other taxoids.

While taxoids have been successful in treating certain types of cancer, they can also cause significant side effects, including neutropenia (low white blood cell count), anemia (low red blood cell count), and peripheral neuropathy (nerve damage). As with all chemotherapy drugs, the use of taxoids must be carefully balanced against their potential benefits and risks.

Intravenous (IV) infusion is a medical procedure in which liquids, such as medications, nutrients, or fluids, are delivered directly into a patient's vein through a needle or a catheter. This route of administration allows for rapid absorption and distribution of the infused substance throughout the body. IV infusions can be used for various purposes, including resuscitation, hydration, nutrition support, medication delivery, and blood product transfusion. The rate and volume of the infusion are carefully controlled to ensure patient safety and efficacy of treatment.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Antineoplastic agents, phytogenic, also known as plant-derived anticancer drugs, are medications that are derived from plants and used to treat cancer. These agents have natural origins and work by interfering with the growth and multiplication of cancer cells, helping to slow or stop the spread of the disease. Some examples of antineoplastic agents, phytogenic include paclitaxel (Taxol), vincristine, vinblastine, and etoposide. These drugs are often used in combination with other treatments such as surgery, radiation therapy, and other medications to provide a comprehensive approach to cancer care.

Deoxycytidine is a chemical compound that is a component of DNA, one of the nucleic acids in living organisms. It is a nucleoside, consisting of the sugar deoxyribose and the base cytosine. Deoxycytidine pairs with guanine via hydrogen bonds to form base pairs in the double helix structure of DNA.

In biochemistry, deoxycytidine can also exist as a free nucleoside, not bound to other molecules. It is involved in various cellular processes related to DNA metabolism and replication. Deoxycytidine can be phosphorylated to form deoxycytidine monophosphate (dCMP), which is an important intermediate in the synthesis of DNA.

It's worth noting that while deoxycytidine is a component of DNA, its counterpart in RNA is cytidine, which contains ribose instead of deoxyribose as the sugar component.

The Maximum Tolerated Dose (MTD) is a term used in medical research, particularly in clinical trials of new drugs or treatments. It refers to the highest dose of a medication or treatment that can be given without causing unacceptable or severe side effects or toxicity to the patient.

Determining the MTD is an important step in developing new medications, as it helps researchers establish a safe and effective dosage range for future use. This process typically involves gradually increasing the dose in a group of subjects (often healthy volunteers in early phase trials) until intolerable side effects occur, at which point the previous dose is considered the MTD.

It's important to note that the MTD may vary between individuals and populations, depending on factors such as age, sex, genetic makeup, and overall health status. Therefore, individualized dosing strategies may be necessary to ensure safe and effective treatment with new medications.

Paclitaxel is a chemotherapeutic agent derived from the bark of the Pacific yew tree (Taxus brevifolia). It is an antimicrotubule agent that promotes the assembly and stabilization of microtubules, thereby interfering with the normal dynamic reorganization of the microtubule network that is essential for cell division.

Paclitaxel is used in the treatment of various types of cancer including ovarian, breast, lung, and pancreatic cancers. It works by inhibiting the disassembly of microtubules, which prevents the separation of chromosomes during mitosis, leading to cell cycle arrest and apoptosis (programmed cell death).

Common side effects of paclitaxel include neutropenia (low white blood cell count), anemia (low red blood cell count), alopecia (hair loss), peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet), myalgias (muscle pain), arthralgias (joint pain), and hypersensitivity reactions.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Camptothecin is a topoisomerase I inhibitor, which is a type of chemotherapeutic agent used in cancer treatment. It works by interfering with the function of an enzyme called topoisomerase I, which helps to uncoil DNA during cell division. By inhibiting this enzyme, camptothecin prevents the cancer cells from dividing and growing, ultimately leading to their death.

Camptothecin is found naturally in the bark and stem of the Camptotheca acuminata tree, also known as the "happy tree," which is native to China. It was first isolated in 1966 and has since been developed into several synthetic derivatives, including irinotecan and topotecan, which are used clinically to treat various types of cancer, such as colon, lung, and ovarian cancers.

Like other chemotherapeutic agents, camptothecin can have significant side effects, including nausea, vomiting, diarrhea, and myelosuppression (suppression of bone marrow function). It is important for patients receiving camptothecin-based therapies to be closely monitored by their healthcare team to manage these side effects effectively.

Neutropenia is a condition characterized by an abnormally low concentration (less than 1500 cells/mm3) of neutrophils, a type of white blood cell that plays a crucial role in fighting off bacterial and fungal infections. Neutrophils are essential components of the innate immune system, and their main function is to engulf and destroy microorganisms that can cause harm to the body.

Neutropenia can be classified as mild, moderate, or severe based on the severity of the neutrophil count reduction:

* Mild neutropenia: Neutrophil count between 1000-1500 cells/mm3
* Moderate neutropenia: Neutrophil count between 500-1000 cells/mm3
* Severe neutropenia: Neutrophil count below 500 cells/mm3

Severe neutropenia significantly increases the risk of developing infections, as the body's ability to fight off microorganisms is severely compromised. Common causes of neutropenia include viral infections, certain medications (such as chemotherapy or antibiotics), autoimmune disorders, and congenital conditions affecting bone marrow function. Treatment for neutropenia typically involves addressing the underlying cause, administering granulocyte-colony stimulating factors to boost neutrophil production, and providing appropriate antimicrobial therapy to prevent or treat infections.

Fluorouracil is a antineoplastic medication, which means it is used to treat cancer. It is a type of chemotherapy drug known as an antimetabolite. Fluorouracil works by interfering with the growth of cancer cells and ultimately killing them. It is often used to treat colon, esophageal, stomach, and breast cancers, as well as skin conditions such as actinic keratosis and superficial basal cell carcinoma. Fluorouracil may be given by injection or applied directly to the skin in the form of a cream.

It is important to note that fluorouracil can have serious side effects, including suppression of bone marrow function, mouth sores, stomach and intestinal ulcers, and nerve damage. It should only be used under the close supervision of a healthcare professional.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Thiophenes are organic compounds that contain a heterocyclic ring made up of four carbon atoms and one sulfur atom. The structure of thiophene is similar to benzene, with the benzene ring being replaced by a thiophene ring. Thiophenes are aromatic compounds, which means they have a stable, planar ring structure and delocalized electrons.

Thiophenes can be found in various natural sources such as coal tar, crude oil, and some foods like onions and garlic. They also occur in certain medications, dyes, and pesticides. Some thiophene derivatives have been synthesized and studied for their potential therapeutic uses, including anti-inflammatory, antiviral, and antitumor activities.

In the medical field, thiophenes are used in some pharmaceuticals as building blocks to create drugs with various therapeutic effects. For example, tipepidine, a cough suppressant, contains a thiophene ring. Additionally, some anesthetics and antipsychotic medications also contain thiophene moieties.

It is important to note that while thiophenes themselves are not typically considered medical terms, they play a role in the chemistry of various pharmaceuticals and other medical-related compounds.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Vomiting is defined in medical terms as the forceful expulsion of stomach contents through the mouth. It is a violent, involuntary act that is usually accompanied by strong contractions of the abdominal muscles and retching. The body's vomiting reflex is typically triggered when the brain receives signals from the digestive system that something is amiss.

There are many potential causes of vomiting, including gastrointestinal infections, food poisoning, motion sickness, pregnancy, alcohol consumption, and certain medications or medical conditions. In some cases, vomiting can be a symptom of a more serious underlying condition, such as a brain injury, concussion, or chemical imbalance in the body.

Vomiting is generally not considered a serious medical emergency on its own, but it can lead to dehydration and other complications if left untreated. If vomiting persists for an extended period of time, or if it is accompanied by other concerning symptoms such as severe abdominal pain, fever, or difficulty breathing, it is important to seek medical attention promptly.

Organoplatinum compounds are a group of chemical substances that contain at least one carbon-platinum bond. These compounds have been widely studied and used in the field of medicine, particularly in cancer chemotherapy. The most well-known organoplatinum compound is cisplatin, which is a platinum-based drug used to treat various types of cancers such as testicular, ovarian, bladder, and lung cancers. Cisplatin works by forming crosslinks with the DNA of cancer cells, disrupting their ability to replicate and ultimately leading to cell death. Other examples of organoplatinum compounds used in cancer treatment include carboplatin and oxaliplatin.

Nausea is a subjective, unpleasant sensation of discomfort in the stomach and upper gastrointestinal tract that may precede vomiting. It's often described as a feeling of queasiness or the need to vomit. Nausea can be caused by various factors, including motion sickness, pregnancy, gastrointestinal disorders, infections, certain medications, and emotional stress. While nausea is not a disease itself, it can be a symptom of an underlying medical condition that requires attention and treatment.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Salvage therapy, in the context of medical oncology, refers to the use of treatments that are typically considered less desirable or more aggressive, often due to greater side effects or lower efficacy, when standard treatment options have failed. These therapies are used to attempt to salvage a response or delay disease progression in patients with refractory or relapsed cancers.

In other words, salvage therapy is a last-resort treatment approach for patients who have not responded to first-line or subsequent lines of therapy. It may involve the use of different drug combinations, higher doses of chemotherapy, immunotherapy, targeted therapy, or radiation therapy. The goal of salvage therapy is to extend survival, improve quality of life, or achieve disease stabilization in patients with limited treatment options.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Vinblastine is an alkaloid derived from the Madagascar periwinkle plant (Catharanthus roseus) and is primarily used in cancer chemotherapy. It is classified as a vinca alkaloid, along with vincristine, vinorelbine, and others.

Medically, vinblastine is an antimicrotubule agent that binds to tubulin, a protein involved in the formation of microtubules during cell division. By binding to tubulin, vinblastine prevents the assembly of microtubules, which are essential for mitosis (cell division). This leads to the inhibition of cell division and ultimately results in the death of rapidly dividing cells, such as cancer cells.

Vinblastine is used to treat various types of cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and others. It is often administered intravenously in a healthcare setting and may be given as part of a combination chemotherapy regimen with other anticancer drugs.

As with any medication, vinblastine can have side effects, including bone marrow suppression (leading to an increased risk of infection, anemia, and bleeding), neurotoxicity (resulting in peripheral neuropathy, constipation, and jaw pain), nausea, vomiting, hair loss, and mouth sores. Regular monitoring by a healthcare professional is necessary during vinblastine treatment to manage side effects and ensure the safe and effective use of this medication.

Neoplasm metastasis is the spread of cancer cells from the primary site (where the original or primary tumor formed) to other places in the body. This happens when cancer cells break away from the original (primary) tumor and enter the bloodstream or lymphatic system. The cancer cells can then travel to other parts of the body and form new tumors, called secondary tumors or metastases.

Metastasis is a key feature of malignant neoplasms (cancers), and it is one of the main ways that cancer can cause harm in the body. The metastatic tumors may continue to grow and may cause damage to the organs and tissues where they are located. They can also release additional cancer cells into the bloodstream or lymphatic system, leading to further spread of the cancer.

The metastatic tumors are named based on the location where they are found, as well as the type of primary cancer. For example, if a patient has a primary lung cancer that has metastasized to the liver, the metastatic tumor would be called a liver metastasis from lung cancer.

It is important to note that the presence of metastases can significantly affect a person's prognosis and treatment options. In general, metastatic cancer is more difficult to treat than cancer that has not spread beyond its original site. However, there are many factors that can influence a person's prognosis and response to treatment, so it is important for each individual to discuss their specific situation with their healthcare team.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Monoclonal antibodies are laboratory-produced proteins that mimic the immune system's ability to fight off harmful antigens such as viruses and cancer cells. They are created by fusing a single B cell (the type of white blood cell responsible for producing antibodies) with a tumor cell, resulting in a hybrid cell called a hybridoma. This hybridoma can then be cloned to produce a large number of identical cells, all producing the same antibody, hence "monoclonal."

Humanized monoclonal antibodies are a type of monoclonal antibody that have been genetically engineered to include human components. This is done to reduce the risk of an adverse immune response in patients receiving the treatment. In this process, the variable region of the mouse monoclonal antibody, which contains the antigen-binding site, is grafted onto a human constant region. The resulting humanized monoclonal antibody retains the ability to bind to the target antigen while minimizing the immunogenicity associated with murine (mouse) antibodies.

In summary, "antibodies, monoclonal, humanized" refers to a type of laboratory-produced protein that mimics the immune system's ability to fight off harmful antigens, but with reduced immunogenicity due to the inclusion of human components in their structure.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

"Pyrroles" is not a medical term in and of itself, but "pyrrole" is an organic compound that contains one nitrogen atom and four carbon atoms in a ring structure. In the context of human health, "pyrroles" often refers to a group of compounds called pyrrol derivatives or pyrrole metabolites.

In clinical settings, "pyrroles" is sometimes used to refer to a urinary metabolite called "pyrrole-protein conjugate," which contains a pyrrole ring and is excreted in the urine. Elevated levels of this compound have been associated with certain psychiatric and behavioral disorders, such as schizophrenia and mood disorders. However, the relationship between pyrroles and these conditions is not well understood, and more research is needed to establish a clear medical definition or diagnostic criteria for "pyrrole disorder" or "pyroluria."

Cisplatin is a chemotherapeutic agent used to treat various types of cancers, including testicular, ovarian, bladder, head and neck, lung, and cervical cancers. It is an inorganic platinum compound that contains a central platinum atom surrounded by two chloride atoms and two ammonia molecules in a cis configuration.

Cisplatin works by forming crosslinks between DNA strands, which disrupts the structure of DNA and prevents cancer cells from replicating. This ultimately leads to cell death and slows down or stops the growth of tumors. However, cisplatin can also cause damage to normal cells, leading to side effects such as nausea, vomiting, hearing loss, and kidney damage. Therefore, it is essential to monitor patients closely during treatment and manage any adverse effects promptly.

Quinazolines are not a medical term per se, but they are a class of organic compounds that have been widely used in the development of various pharmaceutical drugs. Therefore, I will provide you with a chemical definition of quinazolines:

Quinazolines are heterocyclic aromatic organic compounds consisting of a benzene ring fused to a pyrazine ring. The structure can be represented as follows:

Quinazoline

They are often used as building blocks in the synthesis of various drugs, including those used for treating cancer, cardiovascular diseases, and microbial infections. Some examples of FDA-approved drugs containing a quinazoline core include the tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva), which are used to treat non-small cell lung cancer, and the calcium channel blocker verapamil (Calan, Isoptin), which is used to treat hypertension and angina.

Carcinoma, non-small-cell lung (NSCLC) is a type of lung cancer that includes several subtypes of malignant tumors arising from the epithelial cells of the lung. These subtypes are classified based on the appearance of the cancer cells under a microscope and include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC accounts for about 85% of all lung cancers and tends to grow and spread more slowly than small-cell lung cancer (SCLC).

NSCLC is often asymptomatic in its early stages, but as the tumor grows, symptoms such as coughing, chest pain, shortness of breath, hoarseness, and weight loss may develop. Treatment options for NSCLC depend on the stage and location of the cancer, as well as the patient's overall health and lung function. Common treatments include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Leucovorin is the pharmaceutical name for a form of folic acid, also known as folinic acid. It is used in medicine as a medication to reduce the toxic effects of certain chemotherapy drugs, such as methotrexate, that work by blocking the action of folic acid in the body. Leucovorin is able to bypass this blockage and restore some of the necessary functions of folic acid, helping to prevent or reduce the severity of side effects like nausea, vomiting, and damage to the mucous membranes.

Leucovorin may also be used in combination with fluorouracil chemotherapy to enhance its effectiveness in treating certain types of cancer. It is important to note that leucovorin should only be used under the supervision of a healthcare professional, as it can interact with other medications and have potentially serious side effects if not used properly.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

Antimetabolites are a class of antineoplastic (chemotherapy) drugs that interfere with the metabolism of cancer cells and inhibit their growth and proliferation. These agents are structurally similar to naturally occurring metabolites, such as amino acids, nucleotides, and folic acid, which are essential for cellular replication and growth. Antimetabolites act as false analogs and get incorporated into the growing cells' DNA or RNA, causing disruption of the normal synthesis process, leading to cell cycle arrest and apoptosis (programmed cell death).

Examples of antimetabolite drugs include:

1. Folate antagonists: Methotrexate, Pemetrexed
2. Purine analogs: Mercaptopurine, Thioguanine, Fludarabine, Cladribine
3. Pyrimidine analogs: 5-Fluorouracil (5-FU), Capecitabine, Cytarabine, Gemcitabine

These drugs are used to treat various types of cancers, such as leukemias, lymphomas, breast, ovarian, and gastrointestinal cancers. Due to their mechanism of action, antimetabolites can also affect normal, rapidly dividing cells in the body, leading to side effects like myelosuppression (decreased production of blood cells), mucositis (inflammation and ulceration of the gastrointestinal tract), and alopecia (hair loss).

Carcinoma, renal cell (also known as renal cell carcinoma or RCC) is a type of cancer that originates in the lining of the tubules of the kidney. These tubules are small structures within the kidney that help filter waste and fluids from the blood to form urine.

Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for about 80-85% of all cases. It can affect people of any age, but it is more commonly diagnosed in those over the age of 50.

There are several subtypes of renal cell carcinoma, including clear cell, papillary, chromophobe, and collecting duct carcinomas, among others. Each subtype has a different appearance under the microscope and may have a different prognosis and response to treatment.

Symptoms of renal cell carcinoma can vary but may include blood in the urine, flank pain, a lump or mass in the abdomen, unexplained weight loss, fatigue, and fever. Treatment options for renal cell carcinoma depend on the stage and grade of the cancer, as well as the patient's overall health and preferences. Treatment may include surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy.

Diarrhea is a condition in which an individual experiences loose, watery stools frequently, often exceeding three times a day. It can be acute, lasting for several days, or chronic, persisting for weeks or even months. Diarrhea can result from various factors, including viral, bacterial, or parasitic infections, food intolerances, medications, and underlying medical conditions such as inflammatory bowel disease or irritable bowel syndrome. Dehydration is a potential complication of diarrhea, particularly in severe cases or in vulnerable populations like young children and the elderly.

Indole is not strictly a medical term, but it is a chemical compound that can be found in the human body and has relevance to medical and biological research. Indoles are organic compounds that contain a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered pyrrole ring.

In the context of medicine, indoles are particularly relevant due to their presence in certain hormones and other biologically active molecules. For example, the neurotransmitter serotonin contains an indole ring, as does the hormone melatonin. Indoles can also be found in various plant-based foods, such as cruciferous vegetables (e.g., broccoli, kale), and have been studied for their potential health benefits.

Some indoles, like indole-3-carbinol and diindolylmethane, are found in these vegetables and can have anti-cancer properties by modulating estrogen metabolism, reducing inflammation, and promoting cell death (apoptosis) in cancer cells. However, it is essential to note that further research is needed to fully understand the potential health benefits and risks associated with indoles.

Breast neoplasms refer to abnormal growths in the breast tissue that can be benign or malignant. Benign breast neoplasms are non-cancerous tumors or growths, while malignant breast neoplasms are cancerous tumors that can invade surrounding tissues and spread to other parts of the body.

Breast neoplasms can arise from different types of cells in the breast, including milk ducts, milk sacs (lobules), or connective tissue. The most common type of breast cancer is ductal carcinoma, which starts in the milk ducts and can spread to other parts of the breast and nearby structures.

Breast neoplasms are usually detected through screening methods such as mammography, ultrasound, or MRI, or through self-examination or clinical examination. Treatment options for breast neoplasms depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and personal preferences. Treatment may include surgery, radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) medication that is primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by increasing the levels of serotonin, a neurotransmitter in the brain that helps maintain mental balance.

Fluoxetine is available under the brand name Prozac and is also available as a generic medication. It comes in various forms, including capsules, tablets, delayed-release capsules, and liquid solution. The typical starting dose for adults with depression is 20 mg per day, but the dosage may be adjusted based on individual patient needs and response to treatment.

Fluoxetine has a relatively long half-life, which means it stays in the body for an extended period of time. This can be beneficial for patients who may have difficulty remembering to take their medication daily, as they may only need to take it once or twice a week. However, it also means that it may take several weeks for the full effects of the medication to become apparent.

As with any medication, fluoxetine can cause side effects, including nausea, dry mouth, sleepiness, insomnia, dizziness, and headache. In some cases, it may also increase the risk of suicidal thoughts or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider.

Second-generation antidepressants (SGAs) are a class of medications used primarily for the treatment of depression, although they are also used for other psychiatric and medical conditions. They are called "second-generation" because they were developed after the first generation of antidepressants, which include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

SGAs are also known as atypical antidepressants or novel antidepressants. They work by affecting the levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine. However, they have a different chemical structure and mechanism of action than first-generation antidepressants.

Some examples of second-generation antidepressants include:

* Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa)
* Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta)
* Norepinephrine and dopamine reuptake inhibitors (NDRIs) such as bupropion (Wellbutrin)
* Atypical antidepressants such as mirtazapine (Remeron), trazodone, and vortioxetine (Brintellix)

SGAs are generally considered to have a more favorable side effect profile than first-generation antidepressants. They are less likely to cause anticholinergic effects such as dry mouth, constipation, and blurred vision, and they are less likely to cause cardiac conduction abnormalities or orthostatic hypotension. However, SGAs may still cause side effects such as nausea, insomnia, sexual dysfunction, and weight gain.

It's important to note that the choice of antidepressant medication should be individualized based on the patient's specific symptoms, medical history, and other factors. It may take some trial and error to find the most effective and well-tolerated medication for a given patient.

Serotonin uptake inhibitors (also known as Selective Serotonin Reuptake Inhibitors or SSRIs) are a class of medications primarily used to treat depression and anxiety disorders. They work by increasing the levels of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep, among other functions.

SSRIs block the reuptake of serotonin into the presynaptic neuron, allowing more serotonin to be available in the synapse (the space between two neurons) for binding to postsynaptic receptors. This results in increased serotonergic neurotransmission and improved mood regulation.

Examples of SSRIs include fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and escitalopram (Lexapro). These medications are generally well-tolerated, with side effects that may include nausea, headache, insomnia, sexual dysfunction, and increased anxiety or agitation. However, they can have serious interactions with other medications, so it is important to inform your healthcare provider of all medications you are taking before starting an SSRI.

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter that is found primarily in the gastrointestinal (GI) tract, blood platelets, and the central nervous system (CNS) of humans and other animals. It is produced by the conversion of the amino acid tryptophan to 5-hydroxytryptophan (5-HTP), and then to serotonin.

In the CNS, serotonin plays a role in regulating mood, appetite, sleep, memory, learning, and behavior, among other functions. It also acts as a vasoconstrictor, helping to regulate blood flow and blood pressure. In the GI tract, it is involved in peristalsis, the contraction and relaxation of muscles that moves food through the digestive system.

Serotonin is synthesized and stored in serotonergic neurons, which are nerve cells that use serotonin as their primary neurotransmitter. These neurons are found throughout the brain and spinal cord, and they communicate with other neurons by releasing serotonin into the synapse, the small gap between two neurons.

Abnormal levels of serotonin have been linked to a variety of disorders, including depression, anxiety, schizophrenia, and migraines. Medications that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs), are commonly used to treat these conditions.

A drug interaction is the effect of combining two or more drugs, or a drug and another substance (such as food or alcohol), which can alter the effectiveness or side effects of one or both of the substances. These interactions can be categorized as follows:

1. Pharmacodynamic interactions: These occur when two or more drugs act on the same target organ or receptor, leading to an additive, synergistic, or antagonistic effect. For example, taking a sedative and an antihistamine together can result in increased drowsiness due to their combined depressant effects on the central nervous system.
2. Pharmacokinetic interactions: These occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. For example, taking certain antibiotics with grapefruit juice can increase the concentration of the antibiotic in the bloodstream, leading to potential toxicity.
3. Food-drug interactions: Some drugs may interact with specific foods, affecting their absorption, metabolism, or excretion. An example is the interaction between warfarin (a blood thinner) and green leafy vegetables, which can increase the risk of bleeding due to enhanced vitamin K absorption from the vegetables.
4. Drug-herb interactions: Some herbal supplements may interact with medications, leading to altered drug levels or increased side effects. For instance, St. John's Wort can decrease the effectiveness of certain antidepressants and oral contraceptives by inducing their metabolism.
5. Drug-alcohol interactions: Alcohol can interact with various medications, causing additive sedative effects, impaired judgment, or increased risk of liver damage. For example, combining alcohol with benzodiazepines or opioids can lead to dangerous levels of sedation and respiratory depression.

It is essential for healthcare providers and patients to be aware of potential drug interactions to minimize adverse effects and optimize treatment outcomes.

Product labeling, in the context of medicine or healthcare, refers to the information that is required by law to be present on the packaging of a pharmaceutical product or medical device. This information typically includes:

1. The name of the product, often with an active ingredient listed separately.
2. A description of what the product is used for (indications).
3. Dosage instructions and route of administration.
4. Warnings about potential side effects, contraindications, and precautions.
5. The name and address of the manufacturer or distributor.
6. The expiration date or storage conditions, if applicable.
7. Any other relevant information, such as whether the product is subject to additional monitoring.

The purpose of product labeling is to provide accurate and standardized information to healthcare professionals and patients about the safe and effective use of a medical product. It helps to ensure that the product is used appropriately, reducing the risk of adverse events or misuse.

Drug labeling refers to the information that is provided on the packaging or container of a medication, as well as any accompanying promotional materials. This information is intended to provide healthcare professionals and patients with accurate and up-to-date data about the drug's composition, intended use, dosage, side effects, contraindications, and other important details that are necessary for safe and effective use.

The labeling of prescription drugs in the United States is regulated by the Food and Drug Administration (FDA), which requires manufacturers to submit proposed labeling as part of their new drug application. The FDA reviews the labeling to ensure that it is truthful, balanced, and not misleading, and provides accurate information about the drug's risks and benefits.

The labeling of over-the-counter (OTC) drugs is also regulated by the FDA, but in this case, the agency has established a set of monographs that specify the conditions under which certain active ingredients can be used and the labeling requirements for each ingredient. Manufacturers of OTC drugs must ensure that their labeling complies with these monographs.

In addition to the information required by regulatory agencies, drug labeling may also include additional information provided by the manufacturer, such as detailed instructions for use, storage requirements, and any warnings or precautions that are necessary to ensure safe and effective use of the medication. It is important for healthcare professionals and patients to carefully review and understand all of the information provided on a drug's labeling before using the medication.

... is a species of moth of the family Tortricidae. It is found in Guatemala. tortricidae.com Wikispecies has ... Wikimedia Commons has media related to Eugnosta asthenia. v t e (Articles with short description, Short description is ...
... humans Hereditary equine regional dermal asthenia - horses Feline cutaneous asthenia - cats Maudlin, EA; Peters-Kennedy, J ( ... Cutaneous asthenia is a skin disorder caused by a collagen defect. Collagen is the protein that binds the cells of the dermis ...
... is a species of beetle in the family Cerambycidae. It was described by Martins and Galileo in 1990. It is ... BioLib.cz - Hypsioma asthenia. Retrieved on 8 September 2014. v t e (Articles with short description, Short description matches ...
... is similar to the Ehlers-Danlos syndrome of humans. Cats with cutaneous asthenia cannot be grasped by ... Although feline cutaneous asthenia is not curable, there are treatment and management options for the disease. Affected animals ... Feline cutaneous asthenia is a rare inheritable skin disease of cats characterised by abnormal elasticity, stretching, and ... There are two genetic traits linked to feline cutaneous asthenia. One comes from a dominant allele, while the other comes from ...
... (HERDA), also known as hyperelastosis cutis (HC), is an inherited autosomal ... August 2004). "Hereditary equine regional dermal asthenia ("hyperelastosis cutis") in 50 horses: clinical, histological, ... "Cardiac findings in Quarter Horses with heritable equine regional dermal asthenia". Journal of the American Veterinary Medical ... Davis first coined the term hereditary equine regional dermal asthenia (HERDA) after examining 50 horses with stereotypical ...
Excluded from this disorder are: asthenia NOS (R53), burn-out (Z73.0), malaise and fatigue (R53), postviral fatigue syndrome ( ... asthenia". Despite being removed from the American Psychiatric Association's DSM in 1980, neurasthenia is listed in an appendix ...
Asthenia NOS. Excludes: age-related weakness (R54) muscle weakness (generalized) (M62.81) sarcopenia (M6 2.84) senile asthenia ... Senile asthenia. Senile debility. Excludes: age-related cognitive decline (R41.81) sarcopenia (M62.84) senile psychosis (F03) ... weakness/asthenia, and in the ICD-10, also from fatigue lasting under 6 months. The ICD-11 MG22 Fatigue code is also shared ...
Asthenia Weight gain or loss. Usually gain, paroxetine tends to produce more weight gain than other SSRIs.: 58 Confusion ...
... neurocirculatory asthenia, primary neurasthenia, and subacute asthenia. Da Costa himself called it irritable heart and the term ... neurocirculatory asthenia, primary neurasthenia, subacute asthenia and irritable heart) is a psychiatric syndrome which ... Neurocirculatory asthenia is most typically seen as a form of anxiety disorder. "Dorlands Medical Dictionary: Da Costa syndrome ... For example, Oglesby Paul writes that "Not all patients with neurocirculatory asthenia have a cardiac neurosis, and not all ...
Some claim it to be a case of feline cutaneous asthenia, but it is a textbook case of matted fur. In 1975, the Manchester ... In "winged" cats with cutaneous asthenia, the pseudo-wings only occur on the shoulders, haunches, or back, and the cats can ... The second explanation of reports of winged cats is a skin condition called feline cutaneous asthenia, which is related to ... This sometimes happens with cutaneous asthenia. In 1986, a winged cat was reported in Anglesey, Britain, and later shed its ...
"Asthenia - Does It Exist in Space?". Psychosomatic Medicine. 63 (6): 874-80. CiteSeerX 10.1.1.537.9855. doi:10.1097/00006842- ...
Scott DV (October 1974). "Cutaneous asthenia in a cat, resembling Ehlers-Danlos syndrome in man". Veterinary Medicine, Small ... "Ehler-Danlos Syndrome (Cutaneous asthenia, dermatosparaxis)". veterinary-practice.com. October 2016. Retrieved 2019-06-03. ...
Asthenia - Does it exist in space? Psychosom. Med., 63, 874-880. Palinkas, L.A. (1991). Group adaptation and individual ...
Fatigue (9.2%), weight gain (5.0%), asthenia (1.1%). A teratology study conducted in rabbits found that a dose of 150 mg/kg/day ...
This syndrome is often accompanied by asthenia. Alain Carpentier - a member of the French Academy of Sciences and the head the ... It is used to treat Skumin syndrome, light forms of heart failure, anxiety and sleep disorders, and asthenia. The medicine is ...
At the initial stage, asthenia is prevalent and the progress of the disorder is slow. Acute onset can be diagnosed when a large ... Psychoorganic syndrome is often accompanied by asthenia. Psychoorganic syndrome occurs during atrophy of the brain, most ...
The pathological well-being (euphoria) or hyperactivity may produce a state of exhaustion, and profound fatigue or asthenia ... A marked increase in fatigability, or asthenia, is often prominent. This increased weariness may be combined with hyperactivity ...
Three years after making his debut, Guth died from asthenia. Snyder, John (2005). Cubs Journal: Year by Year and Day by Day ...
... is the stallion that is linked to the genetic disease Hereditary Equine Regional Dermal Asthenia (HERDA) in stock ... Inheritance of hereditary equine regional dermal asthenia in Quarter Horses. Vet Dermatol. 2004 Aug;15(4):207-17. Hereditary ... equine regional dermal asthenia ("hyperelastosis cutis") in 50 horses Lab Invest. 1988 Aug;59(2):253-62. An inherited ...
He died on 18 August 1917, due to sarcomatosis asthenia. On 22 December 1910, he married Isabel Marion Johnston (of a Derry ...
Fletcher died of "asthenia due to phthisis pulmonalis" in 1879. "Too Young To Die". TheDeadballEra.com. Retrieved February 19, ...
Main therapeutic areas: Cough & Cold, GERD & Heartburn, Antiviral, Asthenia and Vitamins. Contract Manufacturing Unit: - ...
"It's not specifically about my mother… I feel weird talking about it." "Asthenia" uses real NASA transmissions from the Apollo ...
Couchoud presented in Paris his doctorate thesis on primitive asthenia (1911). He became director of a health center in Saint- ...
These symptoms could consist of asthenia, fever, anorexia, and weight loss. They mostly occur during a severe disease flare. ...
Gastro-intestinal effects and asthenia are the most common adverse events. Bortezomib is associated with peripheral neuropathy ...
Weakness or asthenia is a symptom of a number of different conditions. Weakness may also refer to: Muscle weakness, the ...
Hereditary Equine Regional Dermal Asthenia (HERDA), also known as hyperelastosis cutis (HC). This is caused by an autosomal ...
Chronic campylobacteriosis features a long period of sub-febrile temperature and asthenia; eye damage, arthritis, endocarditis ...
The most common side effects are infusion-related reactions, hypersensitivity and asthenia. Pegunigalsidase alfa was approved ...
Eugnosta asthenia is a species of moth of the family Tortricidae. It is found in Guatemala. tortricidae.com Wikispecies has ... Wikimedia Commons has media related to Eugnosta asthenia. v t e (Articles with short description, Short description is ...
Dr. Ann Rashmir of Michigan State University talks about HERDA. (5:33)
This presentation was previously designated as dry eyes and mouth syndrome (DEMS) or sicca asthenia polyalgia syndrome (SAPS). ... Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome BY ... This presentation was previously designated as dry eyes and mouth syndrome (DEMS) or sicca asthenia polyalgia syndrome (SAPS). ...
Conclusions: : The Sicca Asthenia Polyalgia Syndrome, very close to the Sjögrens disease as for subjective symptoms, leads to ... Comparison of Ocular Dryness Between Patients Affected by Sjögren Patients and Those Affected by SAPS (Sicca Asthenia Polyalgia ... Comparison of Ocular Dryness Between Patients Affected by Sjögren Patients and Those Affected by SAPS (Sicca Asthenia Polyalgia ... Sicca Asthenia Polyalgia Syndrome), which is characterized by symptoms of sicca syndrome with no biochemical marker of auto- ...
This sensation of low tone is what we know as spring asthenia. Asthenia is a clinical term meaning tiredness. ... What is spring asthenia?. This sensation of low tone is what we know as spring asthenia. Asthenia is a clinical term meaning ... How to combat spring asthenia?. To combat spring asthenia, it is important to consume foods rich in vitamins and minerals, ... Some foods that can help combat spring asthenia are: 1. Fruits and vegetables: they are rich in essential vitamins and minerals ...
Asthenia: Tips to beat season in Spring. 2 years ago. by philcityHealth ...
Alaway and Asthenia. This page shows results related to Alaway and Asthenia from the FDA Adverse Event Reporting System (AERS ... Which medications reported to the FDA are most commonly associated with Asthenia? ...
Sorry, no content matched your criteria. ...
Tag: spring asthenia. Spring asthenia: what is it and how to deal with it?. Spring asthenia is a disorder that affects some ...
services for media, marketing, documentation...and for arts sake ...
Asthenia: what is it and how to treat it?. More commonly known as "fatigue", asthenia is a feeling of exhaustion and weakness ...
Tea for Spring Asthenia is a thoughtful composition of natures finest elements, expertly combined to create a symphony of ... Tea for Spring Asthenia, a harmonious fusion of natures finest ingredients designed to invigorate your senses and rejuvenate ... Tea for Spring Asthenia. Introducing our exquisite blend, "Tea for Spring Asthenia," a harmonious fusion of natures finest ... Be the first to review "Tea for Spring Asthenia" Cancel reply. Your email address will not be published. Required fields are ...
Asthenia) :At Effective Physiotherapy & Fitness Clinic body weaknesses are giving technical knockout on daily basis .... ... BODY WEAKNESS (Asthenia). Many people use the term weakness as a means of expressing tiredness, weariness, lack of energy or ...
What is functional asthenia?. What is Asthenia? The term asthenia refers to extreme muscle weakness and lack of energy. It is ... What does the term asthenia mean in medical terms?. The term asthenia refers to physical weakness or a lack of energy. Asthenia ... What is asthenia caused by?. According to an older article, asthenia is a common symptom of various conditions, including: ... How is asthenia treated?. Sulbutiamine is prescribed for the treatment of asthenia, a condition of severe weakness which is ...
Spinal Cord Anatomy Dorsal Column-Medial Lemniscus (fine… Continue reading Asthenia; Types, Causes, Symptoms, Diagnosis, ... Asthenia is a symptom of a number of different conditions. The causes are many and can be divided into conditions that have ... Asthenia; Types, Causes, Symptoms, Diagnosis, Treatment. Asthenia is a symptom of a number of different conditions. The causes ... Types of Asthenia. Muscle fatigue can be central, neuromuscular, or peripheral muscular. Central muscle fatigue manifests as an ...
Hereditary equine regional dermal asthenia (HERDA) is an inherited skin condition primarily found in Quarter Horses that is ... Horses with N/HRD genotype will not be affected by hereditary equine regional dermal asthenia, but are carriers. They may ... Horses with N/N genotype will not have hereditary equine regional dermal asthenia and cannot transmit this hereditary equine ... Alleles: N = Normal/Unaffected, HRD = Hereditary equine regional dermal asthenia. Breeds appropriate for testing: Quarter Horse ...
Asthenia. ) 19. Not Now. ). 18. Stay Together For The Kids. ). 17. Im Lost Without You. ). 16. Anthem Part Two. ). 15. ...
The so-called spring asthenia, a temporary disorder, begins with the arrival of the suffer from spring. ... Five tips to improve Suffer from spring asthenia. To combat these symptoms, you cannot do much more than lead a healthy ... Tidy up the house to avoid spring asthenia. On the other hand, Amaia Elias, interior designer and Marie Kondos official ... The so-called spring asthenia, a temporary disorder, begins with the arrival of the suffer from spring. Its main symptoms are ...
asthenia. Using Samutzs downloader it doesnt matter what Slot, you the Helper choose ...
asthenia. 32/95 (33.7). 33/102 (32.4). 1 (0.7-1.6). diarrhea. 1/95 (1.1). 3/102 (2.9). 0.4 (0-3.4). ...
Asthenia And Fatigue. Advise patients that HYCAMTIN for injection may cause asthenia or fatigue. These symptoms may impair the ... Asthenia. 5. 3. a Death related to sepsis occurred in 2% of patients receiving HYCAMTIN and 0% of patients receiving paclitaxel ... d Constitutional includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, ...
Asthenia. Loss of strength, debility.. Athetosis. Chorea with peculiar tremors of the fingers and toes. ...
Asthenia. 16 (5). 8 (2). 14 (4). 3 (1). Back pain. 18 (5). 11 (3). 13 (4). 4 (1). ...
Adrenal insufficiency (Addison disease) can be classified as primary, which occurs when the adrenal gland itself is dysfunctional, or secondary, also called central adrenal insufficiency, which occurs when a lack of secretion of corticotropin-releasing hormone (CRH) from the hypothalamus or of adrenocorticotropic hormone (ACTH) from the pitui...
What is asthenia? Read on to discover the conditions that might cause asthenia and find out how doctors diagnose and treat it. ... What to know about asthenia (weakness). Medically reviewed by Jenneh Rishe, RN ...
Asthenia-PERSONALUSEONLY, Alakita-Regular, Suffolk Script, Black Seashore Regular, Let ...
Compare Risperidone head-to-head with other drugs for uses, ratings, cost, side effects and interactions.
Asthenia. 9. 5. 15. 11. 21. 9. 7. 7. Flu syndrome. 3. 4. 10. 7. 8. 3. 5. 5. ...
Depakote delayed-release (DR) was approved in 1983 for the treatment of manic episodes associated with bipolar disorder. Depakote DR was subsequently approved (dates unavailable) for the following indications: as monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures as adjunctive therapy in patients with multiple seizure types that include absence seizures prophylaxis of migraine headaches Depakote Sprinkle Delayed- Release Capsules was approved in 1989 as monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures. Depakote extended-release (ER) was initially approved in 2000 for the acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features. Depakote ER was subsequently approved (dates unavailable) for the following indications: monotherapy and
  • Patients may present non-specific systemic symptoms such as fever, asthenia, or nausea. (uab.edu)
  • Spring asthenia is the name given to this temporary disorder that some people may suffer and it appears with symptoms such as sadness, loss of appetite or fatigue . (marnys.com)
  • To compare the mean values of tests for ocular dryness in patients affected by Sjögren's syndrome (SS) and in those affected by SAPS ( Sicca Asthenia Polyalgia Syndrome ), which is characterized by symptoms of sicca syndrome with no biochemical marker of auto-immune disease (no serum auto-antibody, normality of biopsy of salivary glands). (arvojournals.org)
  • The Sicca Asthenia Polyalgia Syndrome, very close to the Sjögren's disease as for subjective symptoms, leads to a less severe objective ocular dryness. (arvojournals.org)
  • Experts do not consider spring asthenia to be a clinical picture, but rather a seasonal one. (marnys.com)
  • The reasons for admission were dominated by oligo-anuria, digestive disorders, dyspnea and physical asthenia. (scirp.org)
  • The majority of patients consult for oligo-anuria, digestive disorders, dyspnea and physical asthenia. (scirp.org)
  • Muscular impairment should be then considered in LA patients with physical asthenia. (natap.org)
  • Asthenia is also among the common side effects described for this antidepressant. (nih.gov)